drugset / Trial / NCT01394263

Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

NCT01394263

Phase 3 Completed 59 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.

Timeline

Start
2000-05
Primary completion
2001-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Goserelin Other / unclassified 10.8 mg Subcutaneous
Subject Histrelin Other / unclassified 50 mg Other